SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The 8-K discloses results of AST SpaceMobile's Annual Meeting held on June 12, 2026, under Item 5.07. The filing reports voting outcomes on three proposals: (i) election of 10 directors, (ii) ratification of KPMG LLP as independent auditor, and (iii) advisory vote on named executive officer compensation. All three proposals passed with substantial majorities, and the detailed vote tallies are provided for each director and proposal.
View raw filing on EDGAR →The filing discloses a securities purchase agreement with 1800 Diagonal Lending for a convertible promissory note with an original issue discount and conversion rights at 61% of the lowest closing bid price over ten trading days, with potential conversion of up to 19.99% of outstanding shares. Item 3.02 explicitly addresses unregistered sales of equity securities under Section 4(a)(2) and Regulation D, and the conversion feature creates significant dilution risk to existing shareholders. This is a classic PIPE-like structure typical of distressed financing at small-cap issuers.
View raw filing on EDGAR →Ocean Capital Acquisition Corp consummated its IPO on June 10, 2026, raising $115 million in gross proceeds ($100 million from the initial offering plus $15 million from the over-allotment option) through entry into material definitive agreements including the Underwriting Agreement, Warrant Agreement, Rights Agreement, Investment Management Trust Agreement, and Sponsor Private Placement Units Purchase Agreement.
View raw filing on EDGAR →The company completed an unregistered private placement of 150,000 units to the Sponsor at $10.00 per unit ($1.5 million aggregate) pursuant to Section 4(a)(2) exemption, simultaneously with the IPO closing.
View raw filing on EDGAR →Three directors—Pok Yu Chow, Hiu Man Cheng, and Hin Wing Wong—were appointed to the Board on May 4, 2026 in connection with the IPO and subsequently appointed to the Audit and Compensation Committees effective June 10, 2026, establishing the governance structure of the newly public company.
View raw filing on EDGAR →William Conkling, Executive Vice President and Chief Financial Officer, resigned effective June 15, 2026. The company disclosed his departure via press release on June 12, 2026, and entered into a separation agreement with consulting fee arrangements.
View raw filing on EDGAR →This is a clear Item 5.07 disclosure of shareholder voting results from Warby Parker's June 8, 2026 Annual Meeting of Stockholders. The filing reports voting outcomes for three proposals: election of three Class II directors (Dave Gilboa, Youngme Moon, and Ronald Williams), ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a material governance event that affects investor understanding of board composition and corporate oversight.
View raw filing on EDGAR →Wheeler Real Estate Investment Trust, Inc. implemented a one-for-four reverse stock split effective June 17, 2026, via amendments to the Company's charter filed with Maryland. This material modification to the rights of security holders affects share structure, trading mechanics, and conversion terms for convertible securities and preferred stock.
View raw filing on EDGAR →Avalo Therapeutics exchanged 4,294.675 shares of Series C Preferred Stock for newly created Series C-1 Preferred Stock in an unregistered transaction with an accredited investor, removing the 4.99% beneficial ownership restriction and allowing the investor to increase ownership to 9.99%. The Series C-1 Preferred Stock includes conversion rights (1,000 shares of Common Stock per preferred share), broad-based weighted average anti-dilution protection, and dividend parity, materially affecting shareholder concentration and dilution risk.
View raw filing on EDGAR →Avalo Therapeutics amended employment agreements for four named executives (CEO Dr. Neil, CFO Sullivan, CMO Dr. Doyle, and CBO Boyd) to modify severance, change-of-control payments, equity acceleration, and 280G tax gross-up provisions.
View raw filing on EDGAR →This Item 1.01 discloses the entry into a material definitive agreement—the Pooling and Servicing Agreement dated May 1, 2026, which established BBCMS Mortgage Trust 2026-5C41 and caused the issuance of commercial mortgage pass-through certificates backed by 33 mortgage loans. The filing also describes a subsequent servicing arrangement change for one loan (The Towers at Cupertino City Center) transferred to a separate BANK 2026-5YR22 securitization as of June 11, 2026. These are material securitization and servicing transactions that would affect investor assessment of the trust's structure and asset composition.
View raw filing on EDGAR →Trinity Biotech entered into an At the Market Offering Agreement with Lucid Capital Markets on June 12, 2026, authorizing the sale of up to $4,352,314 of American Depositary Shares (ADSs). This is a dilutive equity issuance under an ATM program, which allows the company to raise capital through the sale of registered securities at market prices. The filing discloses the material terms, including the 3.0% commission to the sales agent and the underlying registration statement (Form F-3 File No. 333-280391).
View raw filing on EDGAR →The filing discloses a change in the registrant's independent registered public accounting firm: Ernst & Young LLP (EY) will be dismissed effective upon completion of the audit for fiscal year ending June 30, 2027, and Deloitte & Touche LLP has been selected as the new auditor for fiscal year ending June 30, 2028. This is a classic auditor change under Item 4.01, with no adverse circumstances (no disagreements, no reportable events, and no qualified audit opinions noted).
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Evolus's Annual Meeting of Stockholders held on June 11, 2026. The filing presents voting outcomes for three proposals: election of Class II directors (Brady Stewart and Vikram Malik), ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with majority support, and the detailed vote tallies (For/Against/Abstain/Broker Non-Vote) are the core content of the disclosure.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of TheRealReal's June 10, 2026 annual meeting of stockholders. The filing presents voting outcomes for six proposals: election of Class I directors (Caretha Coleman, Karen Katz, Mark McCaffrey), ratification of KPMG LLP as auditor, advisory vote on named executive officer compensation, and three failed management proposals to amend the Certificate of Incorporation. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) are the hallmark of shareholder vote result disclosures required under Item 5.07.
View raw filing on EDGAR →The filing discloses conclusion of a "strategic review process" via press release on June 12, 2026, but the Item 7.01 disclosure provides no substantive detail about the outcome, recommendations, or implications. Without access to Exhibit 99.1, the specific nature of the strategic review conclusion cannot be determined—it could relate to M&A activity, asset sales, operational restructuring, or other material corporate actions. The materiality and event classification depend critically on the press release content, which is referenced but not excerpted in the Item itself.
View raw filing on EDGAR →The filing discloses Amendment No. 2 to a warrant originally issued under a Securities Purchase Agreement dated March 17, 2026. The amendment reduces the exercise price from $16.00 to $3.00 per share for a 90-day period, substantially increasing the likelihood and incentive for exercise. This modification materially enhances the dilutive potential of the warrant and would affect a reasonable investor's assessment of share dilution and capital structure.
View raw filing on EDGAR →OUTFRONT Media entered into a material definitive agreement on June 12, 2026, to issue $500 million in 6.000% Senior Notes due 2034. This debt issuance represents a material capital structure event with detailed covenant restrictions and default provisions that significantly affect the company's financial position and obligations.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Summit Therapeutics' 2026 Annual Meeting of Stockholders held on June 10, 2026, with detailed voting tabulations for four proposals: election of nine directors, ratification of PricewaterhouseCoopers LLP as auditor, non-binding advisory vote on named executive officer compensation, and approval of a stock incentive plan amendment to increase shares by 8,000,000. All proposals were approved by the requisite stockholder vote, making this a clear shareholder vote results disclosure.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from ZipRecruiter's June 9, 2026 Annual Meeting of Stockholders under Item 5.07. The filing reports final voting tallies on three proposals: election of directors (Brie Carere and Mike Gupta), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a material governance event that affects investor understanding of board composition and corporate oversight.
View raw filing on EDGAR →The filing discloses the closing of an acquisition of ThermoKey S.p.A. by Vertiv's wholly-owned subsidiary. This is a material acquisition event that would affect a reasonable investor's assessment of the company's strategic direction and financial position. The disclosure of the acquisition closing is the principal event, even though it is furnished under Item 7.01 (Regulation FD) rather than the more typical Item 1.01 or 2.01.
View raw filing on EDGAR →HPS Corporate Lending Fund discloses a letter regarding its second quarter 2026 tender offer under Regulation FD. While tender offers can be material to shareholders (affecting liquidity and valuation), this disclosure is limited to furnishing a letter without substantive detail in the 8-K itself. The event does not fit neatly into standard categories (not M&A, not exec-related, not financial restatement), making "other_material" the most appropriate classification, though the materiality assessment reflects uncertainty about the tender offer's significance without seeing the full letter.
View raw filing on EDGAR →The Fund discloses preliminary results of a tender offer for approximately 4.7% of outstanding common shares (2,280,500 shares) that expired June 8, 2026, with purchase price based on NAV as of June 30, 2026. While share repurchases are routine for closed-end funds, a tender offer affecting nearly 5% of shares is a material capital allocation event that would affect investor assessment of the Fund's capital structure and share count. This does not fit neatly into the specific taxonomy categories (not M&A, not dilutive issuance, not a routine administrative matter), warranting classification as other_material.
View raw filing on EDGAR →The filing discloses a dividend declaration on common stock and Series B Preferred Shares via press release under Item 2.02 (Results of Operations and Financial Condition). While dividend declarations are material corporate actions affecting shareholder value, this disclosure does not fit the earnings_release category (which typically reports quarterly/annual financial results) nor any other specific event type. The material nature of dividend declarations to investors warrants classification as other_material rather than a routine administrative disclosure.
View raw filing on EDGAR →This exhibit is a formal Report of Voting Results filed pursuant to National Instrument 51-102 Section 11.3, disclosing the results of Aya Gold & Silver Inc.'s annual shareholders' meeting held on June 12, 2026. It tabulates voting outcomes for three resolutions: election of eight directors, appointment of KPMG LLP as auditors, and an advisory vote on executive compensation. The document explicitly states it is furnished "in accordance with section 11.3 of NI 51-102," confirming it is a mandatory shareholder-vote-results disclosure.
View raw filing on EDGAR →This press release discloses the results of Aya Gold & Silver's annual general meeting of shareholders held on June 12, 2026. It reports detailed voting results for the election of eight director nominees (all approved), the appointment of KPMG LLP as auditors, and an advisory vote on executive compensation. The disclosure includes vote counts and percentages for each director and resolution, which is the core content required for shareholder_vote_results classification.
View raw filing on EDGAR →This disclosure reports the monthly NAV per share for Rithm Perpetual Life Residential Trust as of May 31, 2026, broken down by share class (Class J at $20.1602 and Class E at $20.2647) with detailed asset and liability components. While NAV reporting is routine for closed-end funds and trusts, the disclosure of current NAV per share is material to investors in assessing the fund's value and performance. However, this does not fit neatly into the more specific event categories (it is not an earnings release, impairment, restatement, or other discrete corporate action), making "other_material" the most appropriate classification.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the June 10, 2026 Annual Meeting of Stockholders, including election of two Class II directors, ratification of auditors, approval of convertible note issuance and warrant conversion rights, and adjournment authority. The filing directly reports voting outcomes with vote counts for each proposal, which is the core content of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →Shareholders voted at the June 11, 2026 annual meeting on three matters: election of two Class I directors (Victor K. Lee and Jeff Zhou), ratification of Ernst & Young LLP as independent auditor, and advisory approval of 2025 named executive officer compensation. Detailed voting tallies including for, against, withheld, abstentions, and broker non-votes were disclosed.
View raw filing on EDGAR →The company announced a quarterly cash dividend of $2.00 per share, representing a material capital allocation decision affecting shareholder returns.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Fortrea Holdings' 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing reports voting outcomes on three proposals: election of directors (Anshul Thakral, Peter M. Neupert, and William J. Sharbaugh), ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies (For, Against, Withheld, Abstained, Broker Non-Votes) are characteristic of Item 5.07 disclosures and are material to investors assessing board composition and governance outcomes.
View raw filing on EDGAR →Forbright completed its initial public offering on June 11, 2026, issuing 7.9 million shares at $18.00 per share for approximately $142.2 million in gross proceeds, and simultaneously amended and restated its certificate of incorporation and bylaws to establish the capital structure and governance framework for the newly public company.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from ACM Research's 2026 Annual Meeting held on June 10, 2026. The filing reports voting outcomes for two proposals: election of four directors (David H. Wang, Haiping Dun, Tracy Liu, and Charles Pappis) and ratification of Ernst & Young Hua Ming LLP as independent auditor for 2026. All four director nominees were elected and the auditor appointment was ratified by substantial majorities, making this a routine but material governance disclosure required under Item 5.07.
View raw filing on EDGAR →Camp4 held its Annual Meeting of Stockholders on June 10, 2026, with shareholders voting on three proposals: election of three Class II directors (Steven Holtzman, Murray Stewart, and Richard Young), ratification of Ernst & Young LLP as independent auditor, and approval of an amendment to the 2024 Equity Incentive Plan to modify the evergreen provision to include pre-funded warrants in the share calculation. All three proposals passed with detailed vote tallies disclosed.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Comcast's June 10, 2026 annual meeting, covering four proposals: director elections, auditor ratification, advisory compensation vote, and an independent chair proposal. Item 5.07 explicitly requires disclosure of shareholder vote results, and the detailed vote tallies for each proposal constitute material information affecting investor assessment of corporate governance and management accountability.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from GPGI's 2026 Annual Meeting held on June 11, 2026. The filing reports voting outcomes on four proposals: election of four Class II directors, advisory Say-on-Pay approval, Say-on-Frequency determination (annual voting approved), and auditor ratification. All proposals passed with substantial majorities, making this a material disclosure of governance outcomes that investors rely upon to assess board composition and executive compensation oversight.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Hagerty's 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting outcomes for four proposals: election of nine directors (all receiving majority affirmative votes), advisory approval of named executive officer compensation, advisory frequency vote on compensation (one year recommended), and ratification of Deloitte & Touche LLP as independent auditor. The detailed vote tallies and broker non-votes are characteristic of shareholder vote result disclosures required under Item 5.07.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Asana's June 8, 2026 Annual Meeting of Stockholders, covering three proposals: election of three Class III directors, ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents the final vote tallies for each proposal, which is the quintessential content of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Ginkgo Bioworks' 2026 annual meeting of shareholders held on June 11, 2026. The filing presents detailed voting results for three proposals: election of six directors (with separate voting by Class A and Class B shareholders), ratification of Deloitte & Touche LLP as independent auditor, and an advisory vote on executive compensation. All three proposals passed with substantial majorities. Shareholder vote results are material to investors as they determine board composition and affirm key governance decisions.
View raw filing on EDGAR →Caro Holdings entered into an Asset Purchase and Acquisition Agreement to acquire a 49% interest in mining properties in Tanzania, funded through the issuance of 20,000,000 shares of common stock to Goldrange.
View raw filing on EDGAR →This press release announces Phase III clinical trial results for sovleplenib (ESLIM-02 study) in warm antibody autoimmune hemolytic anemia, presented at EHA 2026 Congress. The disclosure highlights that the study met its primary endpoint with statistically significant efficacy data (66% durable response vs 15% placebo, p<0.0001) and a favorable safety profile. While this is a clinical milestone rather than financial results, it represents a material operational and regulatory event: the NMPA has accepted the NDA for priority review and granted Breakthrough Therapy Designation, positioning sovleplenib as a potential commercial product addressing an unmet medical need in a treatment-sparse landscape. The data directly supports regulatory advancement and future revenue potential.
View raw filing on EDGAR →GSK announced that momelotinib received Orphan Drug Designations (ODD) from the FDA and EMA for VEXAS syndrome treatment, with a planned phase II/III ATLAS trial underway. This is a material regulatory milestone for a rare disease indication that would affect investor assessment of the company's pipeline and development strategy, but it does not fit the specific event categories (not an earnings release, M&A activity, executive change, debt issuance, or other named types). The ODD designation and trial advancement represent a significant operational/strategic development in the drug's regulatory pathway.
View raw filing on EDGAR →Noble Romans entered into a material senior secured term loan agreement with Lake Forest Bank & Trust Company on June 10, 2026, for $6.9 million, and simultaneously terminated a prior material definitive agreement. The loan proceeds were used to refinance existing debt obligations, redeem warrants, and pay advisory fees, materially restructuring the company's capital structure and debt obligations.
View raw filing on EDGAR →This exhibit discloses the results of the Company's Annual General Meeting held on June 9, 2026, with detailed voting outcomes on four resolutions: cancellation of Ms. Jannu Binti Babjan's directorship, appointment of Mr. Uwe Henke von Parpart as director, approval of an Employee Stock Option Plan, and consolidation of capital. All resolutions were approved by greater than 50% of shareholders present by polls, making this a clear shareholder_vote_results disclosure.
View raw filing on EDGAR →HF Foods adopted a shareholder rights plan (poison pill) on June 12, 2026, with one Right per share exercisable at $9.55 per one one-thousandth of a share of Series AA Participating Preferred Stock. The plan is triggered by any person or group acquiring 15% or more of Common Stock without Board approval and is designed to deter hostile takeovers by imposing a significant penalty on such acquirers.
View raw filing on EDGAR →The exhibit discloses utilization of an "At the Market" (ATM) sales agreement with Cantor Fitzgerald & Co, announced December 17, 2024. Although no securities were actually issued during the reporting period (December 16, 2025 to June 12, 2026), the disclosure reports on the block admission of 4,000,000 depositary interests representing common shares available under the ATM scheme. ATM agreements represent standing authority to issue equity on a dilutive basis and are material capital-raising mechanisms, particularly for smaller issuers, even when no shares are issued in a given period.
View raw filing on EDGAR →This 8-K Item 5.07 discloses the results of the Company's Annual Meeting of Stockholders held on June 11, 2026, reporting the election of four directors (Andrey Semechkin, Russell Kern, Donald A. Wright, and Paul V. Maier) with vote tallies showing overwhelming support. Director elections are material governance events affecting the composition of the board and thus the registrant's oversight and strategic direction.
View raw filing on EDGAR →Delta Air Lines entered into a new $2.65 billion credit facility on June 11, 2026, which refinances and replaces its existing credit agreement dated November 6, 2023. The facility includes financial covenants, an accordion feature allowing expansion to $3.65 billion, and customary events of default, constituting a material refinancing transaction affecting the company's capital structure and financial flexibility.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Praxis Precision Medicines' 2026 Annual Meeting of Stockholders held on June 10, 2026. The filing presents voting results for three proposals: election of Class III directors (Gregory Norden, Marcio Souza, and William Young), ratification of Ernst & Young LLP as independent auditor, and an advisory vote on executive compensation. All three proposals passed with substantial majorities, making this a material shareholder vote results disclosure.
View raw filing on EDGAR →The company disclosed interim responder analysis data from a Phase 3 clinical trial (CAPTIVATE) for claseprubart in CIDP via an updated corporate presentation posted to its investor relations website. While clinical trial data updates can be material to investors evaluating the company's pipeline and regulatory prospects, this disclosure does not fit neatly into the more specific event categories (e.g., it is not a formal earnings release, M&A activity, or executive change). The interim nature and presentation format suggest this is a material clinical milestone, warranting classification as other_material rather than forcing it into an ill-fitting category.
View raw filing on EDGAR →